07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Micellular paclitaxel: Additional Phase III data

Additional data from an open-label, European Phase III trial in 789 patients with epithelial ovarian cancer showed that 250 mg/m 2 IV Paclical given as a 1-hour infusion plus carboplatin on day 1 of each...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

Micellular paclitaxel regulatory update

Oasmia submitted an MAA to EMA for Apealea/Paclical micellular paclitaxel to treat epithelial ovarian cancer in combination with carboplatin. Paclical is marketed in Russia (see BioCentury, May 4, 2015). The product is a Cremophor-free formulation...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Micellular paclitaxel regulatory update

Russia approved Paclical micellular paclitaxel from Oasmia to treat epithelial ovarian cancer in combination with carboplatin. Oasmia said a launch of the water-soluble formulation of paclitaxel is slated for 2H15. Pharmasyntez (Irkutsk, Russia) has...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

Paclical micellular paclitaxel: Phase III data

An open-label, European Phase III trial in 789 patients with epithelial ovarian cancer showed that 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle met the...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Oasmia, Pharmasyntez sales and marketing update

Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in the Commonwealth of Independent States (CIS) to treat ovarian cancer, lung cancer and second-line breast cancer. Under the deal, Pharmasyntez will...
00:41 , Oct 20, 2012 |  BC Extra  |  Financial News

Oasmia raises $18.3M in rights issue

Oasmia Pharmaceutical AB (SSE:OASM A) raised SEK122.7 million ($18.3 million) through the sale of 24.5 million shares in a rights issue underwritten by Oasmia's two main shareholders, Alceco International and Nexttobe. The price is about...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Paclical micellular paclitaxel: Completed Phase III enrollment

Oasmia completed enrollment of 650 patients in an open-label, European Phase III trial comparing 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle vs. paclitaxel plus...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Oasmia, Orion deal

Oasmia disclosed in its 1Q11 earnings ended July 31 that it and Orion terminated a 2007 deal granting Orion distribution rights to Oasmia's Paclical micellular paclitaxel in Sweden, Denmark, Norway, Finland and Iceland. Oasmia...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Paclical micellular paclitaxel: Interim Phase III data

Interim data from about 400 patients in an ongoing, open-label, European Phase III trial showed that 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle reduced...
07:00 , Aug 8, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.08 to $1.32 on Friday after resubmitting an NDA to FDA for Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder. Alexza expects the...